LEXANOPADOL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H25FN2O
Molecular Weight	364.4558
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN[C@]1(CC[C@@]2(CC1)OCCC3=C2NC4=C3C=C(F)C=C4)C5=CC=CC=C5

InChI

InChIKey=AMXGKMSRYLZAEO-YHBQERECSA-N

InChI=1S/C23H25FN2O/c1-25-22(16-5-3-2-4-6-16)10-12-23(13-11-22)21-18(9-14-27-23)19-15-17(24)7-8-20(19)26-21/h2-8,15,25-26H,9-14H2,1H3/t22-,23-

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800034083 | https://www.medkoo.com/products/7772 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/ae0bb1efb479568dc1a3fddcd91a7ca0.html | https://apps.who.int/iris/bitstream/handle/10665/275695/WHO-EMP-RHT-TSN-2018.1-eng.pdf

Lexanopadol is a potent ORL-1 agonist (opioid receptor like -1), nociceptin receptor agonists and opioid mu receptor agonists. Preliminary evidence suggests that targeting ORL-1 receptors may have synergistic effects with mu receptors hence enhancing the therapeutic profile of Lexanopadol in the treatment of pain. Lexanopadol is particularly suited for the management of moderate to severe chronic pain, including neuropathic pain. Lexanopadol hemicitrate is in phase II clinical trials for the treatment of pain. However there is no recent development reported.

Originator

Approval Year

Patents

Name

Type

Language

LEXANOPADOL

Official Name

English

GRT-13106G

Preferred Name

English

Lexanopadol [WHO-DD]

Common Name

English

lexanopadol [INN]

Common Name

English

LEXANOPADOL [USAN]

Common Name

English

GRT13106G

Code

English

GRT-6006

Code

English

GRT6006

Code

English

TRANS-6'-FLUORO-N-METHYL-4-PHENYL-4',9'-DIHYDRO-3'H-SPIRO(CYCLOHEXANE-1,1'-PYRANO(3,4-B)INDOL)-4-AMINE

Systematic Name

English

SPIRO(CYCLOHEXANE-1,1'(3'H)-PYRANO(3,4-B)INDOL)-4-AMINE, 6'-FLUORO-4',9'-DIHYDRO-N-METHYL-4-PHENYL-, TRANS-

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C170119